AEB071 + Everolimus

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma

Conditions

CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma

Trial Timeline

Dec 5, 2013 → Jun 1, 2016

NCT ID

NCT01854606

About AEB071 + Everolimus

AEB071 + Everolimus is a phase 1 stage product being developed by Novartis for CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01854606. Target conditions include CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01854606	Phase 1	Completed	Dec 5, 2013	Jun 1, 2016	CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma